RxDoctor Payments Data

Michael Page, MD

Colon & Rectal Surgery · Des Moines, IANPI 1295721223

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (43.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Covidien LP at 31.6% of the total. Reporting peaked in 2020 at $2,801 and has fallen 91.5% since, to $237 in 2025.

$4,855in general payments, 2019–2025

Across 85 payments — averaging $57.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Covidien LP$2K
  • Baxter Healthcare$1K
  • Medtronic$389
  • Stryker$388
  • AbbVie$261
  • Merck$156
  • plus $864 from 20 others
$35,937in research payments, 2019–2025

Across 1 payment — averaging $35,937 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$36K

What the payments were for

  • Consulting fees$1,26026%
  • Speaking & faculty fees$1,50031%
  • Food & beverage$2,09543%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few colon & rectal surgery providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$161,443
Medicare patients
304
Services billed
710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates133$8,516
Colestipol Hcl12$2,000
CholestyramineCholestyramine (With Sugar)16$1,526
Cholestyramine LightCholestyramine11$698
Hydrocortisone30$342
Neomycin Sulfate67$330
Procto-Med HcHydrocortisone21$265
Metronidazole81$158
Ondansetron Hcl29$39

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →